8,200 Shares in Revvity, Inc. (NYSE:RVTY) Purchased by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. acquired a new position in Revvity, Inc. (NYSE:RVTY) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 8,200 shares of the company’s stock, valued at approximately $896,000.

Other large investors have also modified their holdings of the company. Parkside Financial Bank & Trust acquired a new position in shares of Revvity in the fourth quarter worth about $25,000. Gladius Capital Management LP raised its position in shares of Revvity by 84.1% in the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after purchasing an additional 106 shares during the period. CENTRAL TRUST Co acquired a new position in Revvity during the 4th quarter valued at $27,000. ORG Partners LLC acquired a new position in Revvity during the 4th quarter valued at $32,000. Finally, JTC Employer Solutions Trustee Ltd acquired a new position in Revvity during the 4th quarter valued at $33,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Down 0.8 %

Shares of NYSE:RVTY traded down $0.86 during trading on Thursday, reaching $101.74. 312,103 shares of the stock were exchanged, compared to its average volume of 843,514. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.77. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $132.54. The stock has a fifty day moving average of $104.70 and a two-hundred day moving average of $101.32. The firm has a market cap of $12.57 billion, a price-to-earnings ratio of 84.79, a price-to-earnings-growth ratio of 2.67 and a beta of 1.09.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.04. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The business had revenue of $649.90 million during the quarter, compared to the consensus estimate of $646.83 million. During the same quarter in the prior year, the company posted $1.01 earnings per share. Revvity’s revenue was down 3.7% compared to the same quarter last year. Research analysts anticipate that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a $0.07 dividend. The ex-dividend date is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. TD Cowen upped their target price on shares of Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday. KeyCorp increased their target price on Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Robert W. Baird increased their target price on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a research note on Tuesday. Stifel Nicolaus raised their price target on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research note on Friday, February 2nd. Finally, UBS Group cut shares of Revvity from a “buy” rating to a “neutral” rating and raised their target price for the company from $105.00 to $125.00 in a research note on Tuesday, January 16th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $118.17.

Insider Buying and Selling at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now owns 92,801 shares in the company, valued at approximately $9,677,288.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.